You are here
Resource Center Editor and Module Editors
President, European Society for Translational Medicine (EUSTM), Vienna, Austria
Dr. Shahzad is currently serving as a President for the European Society for Translational Medicine. Moreover, he is Chairman, Steering Committee for the Global Translational Medicine Consortium. Dr. Shahzad is management committee member of the European Commission’s COST action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT) and also for the European Commission’s COST action on the Development of a European-based Collaborative Network to Accelerate Technological, Clinical and Commercialisation Progress in the Area of Medical Microwave Imaging. Dr Shahzad is Asst. Professor at the School of Medicine, University of Colorado, USA. He is visiting professor at the Basic Medical School, Harbin Medical University and also holds visiting professorship at the First Affiliated Hospital, Harbin Medical University. Dr. Shahzad is serving as an Editor-in-Chief for the ‘New Horizons in Translational Medicine’ (NHTM) and ‘Translational Medicine Case Reports’ (TMCR) journals, published by Elsevier. Dr. Shahzad has advised and participated in establishing Translational Medicine infrastructure for several organizations. Dr. Shahzad has organized several international conferences and is invited chair/speaker for numerous international life sciences conferences.
Editor Biosimilars Module 1
Juan V. Esplugues is Professor of Pharmacology at the University of Valencia and Clinical Pharmacologist at Dr. Peset University Hospital, both in Valencia, Spain. He leads the Digestive and Inflammatory Diseases Research Unit, a large multidisciplinary research group that carries out pharmacological research related to the digestive tract and inflammation.
Professor Esplugues is Vice President of the Scientific Committee of the Foundation for the Promotion of Health and Biomedical Research in the Valencian Community (FISABIO) and leads a research group at the Centro de Investigación Biomédica en Red (CIBERehd), a Spanish national network of groups researching hepatic and digestive diseases. Previously, he was the Scientific Coordinator of the Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC), a government-funded cardiovascular research institute.
Professor Esplugues has published numerous original articles and reviews in prestigious international journals including Gastroenterology, Hepatology, Proceedings of the National Academy of Sciences of the United States of America (PNAS), Immunity, Circulation, Circulation Research, Trends in Pharmacological Sciences, and British Journal of Pharmacology. He has been the Principal Investigator of over 30 national and international research projects.
Editor Biosimilars Module 2
Bruno Flamion, MD/PhD from the University of Brussels, Brussels, Belgium, is a specialist in internal medicine. He obtained a PhD degree in physiology and was a research fellow at the National Institutes of Health in Bethesda, MD, USA (1988–1992) and at the Belgian National Fund for Scientific Research (1992–1996). He has been Full Professor of Physiology and Pharmacology at the University of Namur, Belgium, since 1998.
Professor Flamion was a medical and pharmacological expert for the Belgian Federal Agency for Medicines and Health Products (FAMHP) for 12 years and has worked for the European Medicines Agency (EMA) in London for 10 years, acting as the Belgian member of CHMP (Committee for Human Medicinal Products) and CAT (Committee for Advanced Therapies). He was also Vice Chair of the Pharmacogenomics Working Party, Chair of the Pharmacokinetics Group, and, most importantly, Chair of the Scientific Advice Working Party for 6 years (2005–2010), where he was in contact with most of the major drug development programmes including biosimilars.
Professor Flamion has also chaired the Committee for Reimbursement of Medicines (CTG/CRM) in Belgium (2010–2012). This committee is part of the National Institute for Health and Disability Insurance (INAMI/RIZIV). Bruno Flamion is now managing a consultancy called BFLAM sprl, located in Belgium. His interests lie in clinical pharmacology, drug development (both regulatory and health technology assessment/reimbursement aspects), patient care, and basic research.
Editor Biosimilars Module 3
Luis Puig Sanz is Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau (HSCSP), and Professor of Dermatology at the Universitat Autònoma de Barcelona (UAB) Medical School, both in Barcelona, Spain.
During the past 10 years, Professor Puig’s clinical research has focused on the treatment of psoriasis with biological agents. He is considered to be a key opinion leader in this field both nationally and internationally, having taught at numerous national and international conferences, workshops, and seminars. The results of his research have been published in numerous articles, 121 book chapters, and 11 international book chapters. He has participated in 25 clinical trials to date, acting as Principal Investigator in most cases.
Professor Puig is a member of the Spanish Academy of Dermatology and Venereology, a founding member of several of its working groups, and the current coordinator of the Spanish Psoriasis Group. He is also an aggregate member of the Spanish Society of Rheumatology and its GEAPSO (Grupo Español de Trabajo en Artritis Psoriásica de la Sociedad Española) Group for Research in Psoriatic Arthritis, and of several international societies, including the European Academy of Dermatology and Venereology (EADV), American Academy of Dermatology (AAD), CILAD (Colegio Ibero Latinoamericano de Dermatología), European Society for Dermatological Research (ESDR), American Society of Dermatopathology (ASDP), International Society of Dermatopathology (ISDP), and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Furthermore, Professor Puig is a scientific advisor to the Psoriasis International Network, President of the Fondation René Touraine Scientific Board Executive Committee, a member of the International Psoriasis Council, and a member of the Board of Directors of the European Academy of Dermatology and Venereology.